Hutch News
Results per Page:
Scanning hemagglutinin to predict the future of flu
From the Bloom Lab, Basic Sciences Division and Bedford Lab, Vaccine and Infectious Disease Division
Chromosome segregation requires con-CENP-T-ration
from the Biggins lab, Basic Sciences Division
Unlocking a new path for cystine-dense peptides
From the Olson Lab, Clinical Research Division and the Strong Lab, Basic Sciences and Vaccine and Infectious Disease Divisions
Fred Hutch announces 2018 Harold M. Weintraub Graduate Student Award recipients
Thirteen graduate students selected for prestigious award in biological sciences
A killer is revealed: kambucha yeast poison their competitors
From the Malik, Smith, and Zanders Laboratories (Basic Sciences Division, Fred Hutch and the Stowers Institute)
Tracking influenza evolution within individual patients may help predict trends
From the Bloom Laboratory , Basic Sciences Division
Retargeting homing endonucleases to cleave new DNA sequences
From the Stoddard Laboratory (Basic Sciences Division)
Stalled ribosomes get bumped off
From the Subramaniam Laboratory, Basic Sciences Division
It's asymmetric: the molecular structure of gap junctions
From the Moens Laboratory, Basic Sciences Division
Jump in the LinE to recombine
From the Smith Lab (Basic Sciences Division)
New library of HIV mutants could inform vaccine design
Laboratory manipulation of the AIDS-causing virus reveals evolutionary ‘dead-ends’
Deciphering how influenza escapes neutralizing antibodies
From the Bloom Laboratory, Basic Sciences Division
Light-directed neuron migration
From the Cooper Laboratory, Basic Sciences Division
Good News: GeekWire Award Finalists include Bezos Family Immunotherapy Clinic and Nohla Therapeutics, among others
Celebrating faculty and staff achievements
Only the (insensitive worms) die young
From the Brent Laboratory (Basic Sciences Division)
Domesticated transposons help feng shui DNA
From Malik (Basic Sciences Division, Fred Hutch) and the Yao (Academia Sinica, Taiwan) Laboratories
Immunotherapy shows promise in preventing leukemia relapse
Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years